Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
News|Articles|February 2, 2016
Catalent Expands Singapore Clinical Trials Hub
Author(s)Pharmaceutical Technology Editors
Catalent plans a $4.6 million investment to expand secondary packaging and storage in Asia.
Advertisement
Catalent Pharma Solutions announced on Feb. 2, 2016 an investment of $4.6 million to expand its Singapore clinical supply facility by building GMP space for secondary packaging. The investment will double the ambient storage space and quadruple cold storage capacity, the company reports.
Established in 1998, Catalent’s Singapore site provides clinical supply services including project and supply chain management, comparator sourcing, clinical label printing, secondary packaging, clinical storage, import/export management, importer of record service, and returns and destruction management services. It has served as a key regional hub for studies in Australia, Singapore, Korea, Hong Kong and other countries in Southeast Asia.
Source:
Advertisement
Related to this article
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
Ravi Kiran Kaja, PhD, explains how USP’s industry-wide initiative aims to build confidence in trace-level extractables and leachables results.
AI accountability, faster FDA pathways, rare disease CMC review, and next-gen GLP-1 formulation lead this week’s PharmTech roundup.
MASH and cardiomyopathy AI collaboration: AstraZeneca pays insitro $40M upfront for target discovery, then leads clinical development and CMC planning.
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about rare disease treatment development and navigating the FDA’s Rare Pediatric Disease Priority Review Voucher Program.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
2
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
3
FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note
4
Nitrosamine Problems and Industry Solutions: PharmTech Explained
5